AstraZeneca Pharma India Limited (BOM:506820)
India · Delayed Price · Currency is INR 9,535.45
+73.60 (0.78%)
At close: Oct 31, 2025
AstraZeneca Pharma India Revenue
AstraZeneca Pharma India had revenue of 5.26B INR in the quarter ending June 30, 2025, with 35.81% growth. This brings the company's revenue in the last twelve months to 18.55B, up 33.69% year-over-year. In the fiscal year ending March 31, 2025, AstraZeneca Pharma India had annual revenue of 17.16B with 32.48% growth.
Revenue (ttm)
18.55B
Revenue Growth
+33.69%
P/S Ratio
12.85
Revenue / Employee
23.13M
Employees
802
Market Cap
238.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | 8.14B | -182.50M | -2.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 10.00T |
| Life Insurance Corporation of India | 9.04T |
| State Bank of India | 3.50T |
| Larsen & Toubro | 2.76T |
| HDFC Bank | 2.68T |
| Tata Consultancy Services | 2.58T |
| ICICI Bank | 1.91T |
| Bharti Airtel | 1.84T |
AstraZeneca Pharma India News
- 19 days ago - AstraZeneca Pharma India to launch hyperkalemia treatment ‘Lokelma’ in November 2025 - Business Upturn
- 4 weeks ago - AstraZeneca Pharma India secures CDSCO approval for additional indication of Enhertu - Business Upturn
- 7 weeks ago - AstraZeneca Pharma receives Rs 60.49 crore NPPA show cause notice over Symbicort pricing - Business Upturn
- 2 months ago - AstraZeneca Pharma shares rise over 2% after company swings back to profit in Q1 - Business Upturn
- 2 months ago - AstraZeneca Pharma Q1 Results: Revenue up 36% YoY to Rs 526 crore, Net Profit at Rs 55 crore - Business Upturn
- 3 months ago - AstraZeneca Pharma gets CDSCO approval to import and sell Imfinzi for additional indication - Business Upturn
- 5 months ago - AstraZeneca Pharma India shares rally over 7% after strong Q4 results - Business Upturn
- 5 months ago - AstraZeneca Pharma receives CDSCO nod for expanded use of Fasenra in India - Business Upturn